Interchange Capital Partners LLC Lowers Holdings in Gilead Sciences, Inc. $GILD

Interchange Capital Partners LLC trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 87.3% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 240 shares of the biopharmaceutical company’s stock after selling 1,648 shares during the period. Interchange Capital Partners LLC’s holdings in Gilead Sciences were worth $27,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Smallwood Wealth Investment Management LLC purchased a new position in Gilead Sciences in the first quarter worth approximately $25,000. Activest Wealth Management grew its position in Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares during the period. Harbor Asset Planning Inc. purchased a new position in Gilead Sciences in the second quarter worth approximately $27,000. Goodman Advisory Group LLC purchased a new position in Gilead Sciences in the first quarter worth approximately $29,000. Finally, Colonial Trust Advisors boosted its position in shares of Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 213 shares during the period. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total value of $354,240.00. Following the sale, the insider directly owned 110,193 shares in the company, valued at $13,011,589.44. This trade represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the sale, the chief financial officer owned 157,055 shares in the company, valued at approximately $18,545,054.40. This represents a 1.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 61,500 shares of company stock worth $7,142,140 over the last ninety days. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Up 0.2%

Shares of NASDAQ GILD opened at $120.94 on Monday. The stock has a market cap of $150.06 billion, a P/E ratio of 24.09, a PEG ratio of 0.83 and a beta of 0.34. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. Gilead Sciences, Inc. has a 12-month low of $86.08 and a 12-month high of $124.61. The business’s fifty day simple moving average is $115.47 and its 200-day simple moving average is $111.11.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period last year, the firm earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were paid a $0.79 dividend. The ex-dividend date was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is currently 62.95%.

Analysts Set New Price Targets

Several research analysts have recently commented on GILD shares. TD Cowen raised their price target on Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research report on Thursday. Daiwa Capital Markets upgraded Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target for the company in a research report on Tuesday, August 19th. JPMorgan Chase & Co. raised their price target on Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Wolfe Research raised their price target on Gilead Sciences from $135.00 to $140.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and raised their price target for the stock from $108.00 to $127.00 in a research report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and a consensus price target of $122.61.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.